Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human papillomavirus bivalent vaccine (types 16, 18)
- Development stage
- Unknown
- Lead developer
- Walvax Biotechnology
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Walrinvax is a bivalent human papillomavirus (HPV) vaccine developed by Shanghai Zerun Biotechnology, a subsidiary of Walvax Biotechnology. It is designed to protect against high-risk HPV types 16 and 18, which are the primary causes of cervical cancer and its precursor lesions globally. The vaccine consists of recombinant L1 capsid proteins expressed in the yeast *Pichia pastoris*, which self-assemble into non-infectious virus-like particles (VLPs). It is formulated with an aluminum hydroxide adjuvant to enhance the immune response. Walrinvax was approved by China's National Medical Products Administration (NMPA) in March 2022 for use in females aged 9 to 30 years. It represents the first yeast-expressed HPV vaccine to reach the market, providing a cost-effective alternative to vaccines produced in insect-cell or E. coli systems.
- Brand names
- Walrinvax沃泽惠
- Other names
- human papillomavirus bivalent vaccine (16/18)HPV 16/18 vaccineZerun HPV vaccineWalvax HPV vaccine
02
Targets
Human papillomavirus type 18 L1 major capsid proteinHPV16 (Human papillomavirus type 16)
Beyond the preview
Go deeper on human papillomavirus bivalent vaccine (types 16, 18).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human papillomavirus bivalent vaccine (types 16, 18).